Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Vol. 001, Issue 03, Pg. No.: 045 – 060 Review Article
TheJournalofPharmaceuticalSciencesandMedicinalResearch
© 2021 The Journal of Pharmaceutical Sciences and Medicinal Research Page | 45
Potential application of Colonic drug delivery system in prevention and treatment of
Colorectal Cancer
Mudassir Ansari, M. Pharma;1 Kavita Singh, M. Pharma, Ph.D.*
1 Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM’s NMIMS
University, Mumbai, India.
1 Corresponding Author: Dr. Kavita Singh, Shobhaben Pratapbhai Patel School of Pharmacy and
Technology Management, SVKM’s NMIMS University, Mumbai, India.
1 Corresponding author’s email: [email protected]
ARTICLE HISTORY
Received On: Final Revision Revised On: Accepted On:
17 July 2021 05 August 2021 15 August 2021
DOI 10.53049/tjopam.2021.v001i03.011
Abstract
Colorectal cancer (CRC) is the second leading cause of cancer related deaths in USA. The current
regimen used to treat colorectal cancer has many side effects and have higher drug distribution in other
tissues. Physical activity and diet play major role in prevention of Colon cancer which is briefly
discussed in this paper. Colon targeted drug delivery system (CoDDS) is found to be a promising
approach to target the drug specifically to colon. This review provides the description of various colon
targeted approaches that can be used to treat CRC. Factors to be consider while designing CoDDS
include pH of GIT, Transit time of GI tract and Microbiota of colon. This review will discuss the staging
and standard treatments modalities for CRC.
Keywords: Colorectal cancer, pH sensitive system, microbial triggered system, pH and microbial
triggered system, pH and time dependent system, bioadhesive system
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 46
1.0 INTRODUCTION
Colorectal cancer (CRC) is the third leading cancer diagnosed all over the world when both men and
women are considered 1,2,3. According to American Cancer Society, in USA alone the number of
colorectal cancer diagnosed in 2014 was 136,830 1,4,5. Colorectal cancer constitutes 10% of all cancers
with a slightly higher risk of occurrence in men then in women 3,4. As far as death rates are concerned, in
USA, colorectal cancer is the second highest cause of cancer related deaths when both men and women
are combined and third highest when both the sexes are considered separately 1,3,6 . In 2014, deaths due
to colorectal cancer in USA were around 50,310 while in 2015 the number of reported deaths was
49,700 1,4,5. There was a major decline in the mortality rate of CRC patient in 2015 as compared to its
previous year which is mainly attributed to the advancement and awareness of colorectal cancer
screening and treatment 6. A study states that Indians are also at a higher risk of colorectal cancer
especially those who have migrated to USA and UK mainly due to change in the dietary habits and
lifestyles 1. Colorectal cancer mainly affects the people at the median age of 70 years 5,6 .
The major risk factor for CRC is the development of benign adenomatous polyps (adenomas) a pre-
cancerous lesion which if not treated can finally result in CRC. Transformation of adenomatous polyps
to adenocarcinoma is a result of multistep genetic and epigenetic processes. Its takes around 10 to 15
years for the polyps to develop into cancer 1,3,7–12. The growth and spread of colorectal cancer adopt a
systematic fashion, the tumor starts from the mucosal lining, if not treated properly propagates into the
wall of colon and rectum draining in to the blood and lymph vessels. Thereafter, it starts metastasizing to
the lymph node and distant organs such as liver, lungs, ovary etc 1,3,4. Over the past few years, ample of
fruitful research was carried out for the treatment of CRC probing epigenetic therapy. This novel path
has shown promise in the treatment and prevention of CRC.
Colon targeted drug delivery system (CoDDS) has gained remarkable progress in recent years aimed at
treating local complications including Colorectal cancer, Chron’s disease, Ulcerative colitis etc where
the conventional dosage form is not able to deliver the drug in required concentrations. CoDDS is not
only confined to delivering the drugs locally but it is also used for the systemic delivery of proteins, ant
diabetic drugs, antiasthmatic drugs. CoDDS have also been explored for the chronotherapy of various
diseases including rheumatoid arthritis, angina pectoris, nocturnal asthma etc 1,13–16. The concept and
aim of CoDDS is to deliver the drugs safely to the colon by protecting (in terms of drug release,
absorption and enzymatic degradation) it from the upper GIT including stomach and small intestine 16–19.
Drugs can be targeted to the colon either rectally or orally but the latter is always preferred due to high
variability as far as drug distribution is concerned, thus targeting specific sites of colon is a drug delivery
challenge 1,6,14,15,19. Patient compliance is also a matter of concern when drug is administered rectally 15.
Moreover, oral drug delivery constitutes 50% of the total delivery systems in the market and mostly
preferred due to patient compliance and ease of manufacturing 3,20,17. This review aims to explore the
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 47
pathophysiology and treatment of CRC with an aim to discuss the formulation strategies that have been
adopted for targeting drugs to the colon for the treatment and prevention of colorectal cancer.
2. PATHOPHYSIOLOGY OF COLORECTAL CANCER
The exact pathophysiology of CRC is still unknown. An ample amount of research is carried at
molecular level in order to understand the genetic involvement of colorectal cancer. Innumerable genes
have been identified which plays a direct or indirect role in the development of CRC. These genes are
divided into tumor suppressor gene and oncogene. Colorectal cancer is mainly caused due to the
mutation happening in these gene. These mutations can be inherited or acquired in a patient’s life 3. The
overall role of these gene in the development and progression of CRC is described in Table 1.
Table 1. Involvement of various genes in the pathophysiology of colorectal cancer
(Modified from Ref 3)
Categories of
gene Genetic defects Genes Pathophysiology
Tumor
suppressor
gene
Instability
in chromosomes
APC Somatic mutation of APC leading to sporadic
CRC, germ line mutation of APC causes FAP.
It also activates Wnt signalling due to the
failure in degrading beta catenin oncoprotein
TP53 Germ line mutation
SMAD4 Germ line mutation
PTEN Germ line mutation that causes the activation of
PI3K signalling pathway
Defects in DNA
mismatch repair
system
MLH1,
MSH2,
MSH6, MYH
Germ-line mutation causes accumulation of
oncogenic mutations and leads to tumour
suppressor loss
Aberrant
DNA
methylation
MLH1 Hyper-methylation of
CpG islands causes silencing of the promoter
region of the genes in mismatch-repair system
Oncogenes
Defects in DNA
mismatch repair
system
RAS, BRAF Activates MAP kinase signalling pathway
Abbreviations: APC, Adenomatous polyposis coli; TP53, Tumor protein 53; SMAD4, Mothers against
decapentaplegic homolog 4; PTEN, Phosphatase and tensin homolog; PI3K, Phosphatidylinositol-4,5-
bisphosphate 3-kinase; MLH1, MutL homolog 1; MSH2, MutS protein homolog 2; MSH6, MutS protein
homolog 6; MYH, MutY Homolog; RAF, RAF proto-oncogene; BRAF, B-RAF proto-oncogene.
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 48
3. TREATMENT OF COLORECTAL CANCER
There are six standard treatments for the management of colorectal cancer. The treatments include 19
surgery, radiation therapy, chemotherapy, targeted therapy, radiofrequency ablation, cryosurgery. Each
of these treatments are used depending upon the stages of colorectal cancer.
3.1. Surgery
Surgery is the primary treatment when the tumor is not metastasized throughout the body and it is the
only treatment in stage 0 and stage 1 colon cancer 5. Depending upon the severity of cancer, surgery can
be of various types as follows:
3.1.1. Local expurgation
In this type of surgery, the cancer is excised from the abdominal wall without invasion. In order to
perform this, a long tubing holding camera and cutting tool is used. This tube is inserted into the colon
and the portion of the colon where the cancer resides is removed along with some nearby tissues. The
term polypectomy is used when the cancer is detached in the form of polyps. This procedure is
implemented when the tumor is in the initial stage and can be easily treated without resection 6,21.
3.1.2. Incision of the colon
Incision is performed when the tumor has grown in each of the layers of colon. This involves an invasive
procedure whereby the affected part of the colon is cut off with some nearby healthy tissues and the two
healthy ends of the resected colon is sewed. This procedure is termed as partial colectomy,
hemicolectomy or segmental resection. In some cases, it is not possible to sew both the healthy ends, in
such circumstances colostomy is done where a small hole is made outside the body to which the bag is
attached for the collection of waste. Nearby lymph nodes are also removed and tested for the presence of
trace number of cancers. Total colectomy is mainly done when the person is suffering from familial
adenomatous polyposis where the whole colon containing polyps is removed 22,23.
3.2. Radiation therapy
Radiation therapy is mainly given after surgery to ensure the killing of tumor cells in other parts of the
body where the cancer has spread. It is also used for the patients who are not liable enough of
performing surgery. It uses X rays of high energy and other types of radiation depending upon the stage
of colon cancer. Radiation therapies are given in two form viz. external beam radiation and internal
beam radiation. In external beam radiation the radiations are provided outside of the body by using
machines while internal beam radiation utilizes radioactive material in the form of pellet or attached to
the tubes and are inserted towards the tumor site 5,22.
3.3. Ablation
This technique involves the destroying of tumor cells without any kind of surgical intervention. Ablation
are of two types viz. radiofrequency ablation and ethanolic ablation. Radiofrequency ablation involves
the usage of a very thin probe which is introduced through the skin t the tumor site such that it passes
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 49
into the tumor. After this, a high frequency radio waves are passed which kills the tumor by heating it.
This process is carried out using local anaesthesia. Sometimes, an incision has to be made in the
abdomen from where the probe is inserted and destroys the tumor cells. Ethanolic ablation involves the
injection of concentrated ethanol at the tumor site so as to directly destroy the tumor cells 5,22.
3.4. Cryotherapy
Cryotherapy is a technique that can kill the tumor cells by freezing it with the help of a thin metal probe.
Ultrasound is used to guide the probe through the skin to reach the tumor cells. This is followed by
passing a very cold gas, which can freeze the tumor leading to destruction of the cancer cells. It is
commonly addressed as Cryosurgery, which includes open cryosurgery, laparoscopic cryosurgery, and
percutaneous cryoablation 22.
3.5. Chemotherapy
Chemotherapy is defined as the use of anti-cancer drug to kill tumor cells or stop its growth and
propagation. Chemotherapy is classified into systemic chemotherapy and regional chemotherapy.
Systemic chemotherapy involves the administration of anti-cancer drug directly into the blood stream
either orally or through injections. In regional chemotherapy the drugs are incorporated directly into the
organs where the chances of metastasis are higher, this prevents the encounter of drugs to other parts of
the body and thus minimizing the side effect. Hepatic artery infusion is one of the examples of regional
chemotherapy whereby the drug is administered into the hepatic artery through infusion, the blood flow
present in the hepatic artery will direct the drug only to the liver thus preventing the exposure to other
organs. Depending upon the stages of colon cancer, chemo can be administered before and after surgery.
When given before surgery it is called as neoadjuvant chemotherapy which mainly deals with decreasing
the size of tumor so that the surgery can be done easily. Adjuvant chemotherapy involves the
administration of drug after surgery to ward off the remaining tumor cells if at all present in the body.
Chemotherapy is also given when cancer has metastasized so as to increase the survival rate of patient
by decreasing the size of tumor. The side effects of chemotherapy include hand foot syndrome,
neuropathy, increase chances of infection etc 5,6,22.
3.6. Targeted therapy
Targeted therapy involves the usage of biologics to specifically attack the tumor cells without harming
others. It can be given alone or along with chemotherapy when chemotherapy fails to show its inhibitory
effect on cancer cells. Targeted therapy delivers drug directly to the colon, this increases drug
concentration in the colonic tissue which ultimately leads to reduction of doses. This therapy mainly
involves the usage of monoclonal antibodies and angiogenesis inhibitor to circumvent the tumor cells.
The main advantage of targeted therapy over chemotherapy is reduction in side effects due to its
specificity 5,22. Drugs used in the treatment of CRC include 5-FU, leucovorin calcium, capecitabine,
irinotecan hydrochloride, oxaliplatin, regorafenib, trifluridine, tipiracil hydrochloride, ziv-aflibercept,
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 50
bevacizumab, cetuximab, ramucirumab, panitumumab. Combination therapy for the treatment of
colorectal cancer are CAPOX- Capecitabine and oxaliplatin, FOLFIRI- 5-FU, leucovorin, and
irinotecan, FOLFIRI-BEVACIZUMAB- 5-FU, leucovorin, irinotecan and bevacizumab, FOLFIRI-
CETUXIMAB- 5-FU, leucovorin, irinotecan and cetuximab, FOLFOX- 5-FU, leucovorin, and
oxaliplatin, FU-LV- 5-FU and leucovorin, XELIRI- Irinotecan and capecitabine, XELOX- Capecitabine
and oxaliplatin, FOLFOXIRI- Leucovorin, 5-FU, oxaliplatin, and irinotecan 24.
4. CHEMOPREVENTION OF COLON CANCER
Chemoprevention is defined as the treatment of precancerous lesions by using dietary compounds and/or
synthetic substances so as to reverse, halt or retard the process of carcinogenesis, and to enhance the
biological protective mechanisms that will lead to genomic conformity 25–27. Chemoprevention is the
best approach to deal with malignancy because cancer treatments decrease the life quality of patients
along with an ample of side effects associated with it along with a horrendous cost of treatment 28–30.
The overall mechanism of colonic chemoprevention involves the inhibition of alteration at genetic and
epigenetic levels that leads to colon carcinogenesis. Some of the mechanisms comprises the activation of
DNA repair machinery and apoptotic pathways, inhibition of uptake pathways to retard the uptake of
carcinogens by cells, modulation of polyamine metabolisms, growth factors, immune response,
hormonal activity and signal transduction 25,26.
The development of colon cancer is not a one step process involving single gene alterations, rather it
involves a series of pre malignant lesions with a huge horde of genetic variations. Thus, an ample of
changes at the molecular level transform the normal cells into a malignant lesion. Therefore,
chemoprevention can be better achieved by targeting these changes and thus protecting the
transformation of normal epithelia to colon carcinoma 26,28,29 (Fig. 1). Report suggests that 50% of
neoplasm can be prevented by adopting primary and secondary strategies. These strategies are as
follows: 26,31–33
4.1. Physical activity
Studies proposed that regular physical activity is linked with the protection of colorectal cancer. A meta-
analysis of 21 studies shows a marked reduction of 27% of getting colon cancer both in the proximal and
distant part of colon when the individual who are least active are compared to the one who is most.
4.2. Diet
Studies on chemoprevention shows a remarkable effect of dietary factors on the prevention of colon
cancer. Some of which include folate, omega 3, calcium, vitamins, dietary fibers etc.
4.2.1. Fruits and vegetables
In an observational cohort study, a comparison was made between individuals having less than 1.5
servings of fruits and vegetables per day with individuals having more than 2.5 servings. Result shows a
reduce risk of colon cancer in individuals having more than 2.5 servings while there is no risk reduction
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 51
in individuals having less than 1.5 servings. Another study suggested the reduction in the risk of colon
cancer if the daily consumption of fruits and vegetables is more than 800 g.
4.2.2. Dietary fibres
Dietary fibers adsorb carcinogens present in feces, modulate bile acid metabolism, enhances short-chain
fatty acids production and thus reducing the risk of colon cancer.
Fig. 1. Adenoma carcinoma sequence and the target for chemoprevention
4.2.3. Vitamin B
A deficiency of folate increases the risk of colon cancer by causing the mutation of p53 gene. Long term
folate intake of ≥ 800 μg/dl have been noticed to suppress the risk associated with colon cancer.
4.2.4. Omega 3
Omega 3 had been proven to play a role in the prevention of colon cancer. Studies have shown that the
consumption of fish is linked to the reduction of colon cancer risk by 12%. The best report is from
randomized trial which shows a marked reduction in the occurrence of adenomas with omega-3 in
patient suffering from familial adenomatous polyposis.
4.3. Drugs
Many drugs have been tested from the past decades to prevent colon cancer 25,26,27,31,34,33. These drugs
are well described in Fig. 1 and Table 2.
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 52
Table 2. List of chemo preventive agents in CRC
Abbreviations:
COX, Cyclo-oxygenase; PPAR-Y, Peroxisome proliferator-activated receptor gamma; CDK, Cyclin
dependent kinase; MMP, Matrix metalloproteinase; iNOS, Induce nitric oxide synthase.
Target Class of drug Mechanisms
COX2 NSAID
Inhibition of COX.
Cyclooxygenase-independent
pathway.
PPAR- Y PPAR-Y ligands Cellular proliferation.
Regulation of inflammatory cytokine.
Ornithine decarboxylase a-Difluoromethylornithine Blockade of polyamine synthesis.
Inhibition of ornithine decarboxylase.
S-adenosyl methionine
decarboxylase Folate
Metabolism of purine and thymidine
for DNA and RNA synthesis.
S-adenosylmethionine (SAM)
formation; methylation maintenance.
Bile acids Calcium
Inhibition of proliferation. Induction
of cell differentiation. Binding of bile
and fatty acid.
Vitamin D receptor Vitamin D Growth inhibition. Elevation of
cellular differentiation.
Bile acids Inulin
Enhanced calcium absorption.
Direct & indirect effects on colorectal
epithelium.
Farnesyl-transferase Farnesyl-transferase
inhibitors (FTIs)
Induction of apoptosis in tumor cells.
Ras activation reversal.
Epidermal growth
factor receptor EKB-569
Inhibition of epidermal growth factor
receptor kinase.
Tyrosine kinase STI-571 Inhibition of Bcr-Abl tyrosine kinase.
Cyclin-dependent kinase CDK inhibitors Cell cycle control.
Matrix metalloproteinase MMP inhibitors Basement membrane integrity.
p53 Wild-type p53 Apoptosis with p53 mutation.
iNOS and COX2 Resveratrol, Pterostilbene Epigenetic modulation.
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 53
5. COLON TARGETED MULTIPARTICULATE DRUG DELIVERY SYSTEM
Multiparticulate drug delivery system (MDDS) involves the usage of pellets, beads, granules,
microsphere, spheroids, mini tabs, microparticles and nanoparticles. MDDS having a particle size of
more than 200 μm have a very low transit time and also due to ease in the uptake of micron and
submicron particles by inflamed cells a multiparticulate approach is predictable to give enhanced
pharmacological effects in the colon. In comparison to single unit system, MDDS have several
advantages which comprises of easy passage of the system through the GIT owing to less variability
between subjects, uniform dispersion throughout the GIT thus causing uniform absorption and enhanced
bioavailability, reduction in systemic toxicity due to prevention of dose dumping, decrease of local
irritation, estimation of gastric emptying 35, 36.
6. FACTORS TO BE CONSIDERED IN DESIGNING COLON TARGETED DRUG
DELIVERY SYSTEMS
The factors that are considered for designing CoDDS includes:
6.1. pH of GIT
This is one of the most important factors which is to be considered in designing CoDDS. This is the
primary approach utilizes gastrointestinal pH in delivering drugs to the colon. pH of GI tract is highly
variable between individuals and also affected by fed and fasted state. Disease of GIT have a greater
impact on pH especially IBD which decreases the pH of the colon to 5.3. The details of pH in every
segment of GIT are given in Table 3 6,13,17.
Table 3. pH of various segments of gastrointestinal tract
Regions of GIT pH
Stomach 1.5 – 3 (fasted state)
4 – 5 (fed state)
Small intestine
Duodenum
Jejunum
Ileum
3 – 6 (fasted state)
1.7 – 4.3 (fed state)
5.4
7 – 8
Cecum 5.5 – 7
Colon
Ascending colon
Transverse colon
Descending colon
Sigmoid colon
6.4
6.6
7
7 – 8
Rectum 7 – 8
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 54
Anal canal 7 – 8
6.2. Transit time of GI tract
Like pH, transit time of GIT is highly variable and depends on fed and fasting condition of the subject.
Disease also has a great influence on GI transit time e.g., patient suffering from ulcerative colitis and
diarrhoea has increased colon transit time than normal. Transit time of gastrointestinal tract also depends
upon the dosage form size and density 6,13,15. Transit time of small intestine is independent of the fed and
fasting condition 6,15. One of the approaches uses the concept of GI transit time for delivery of drugs to
the colon. The transit time is well explained in Table 4 13.
Table 4. Transit time of various segments of GIT
Region of GIT Transit time (h)
Stomach < 1 (fasted)
>3 (fed)
Small intestine 3 – 4
Colon 20 – 30
6.3. Microbiota of colon
There are clusters of bacteria residing in the colon both aerobic and anaerobic that are responsible for
various biochemical activities which include metabolism of xenobiotics, carbohydrate fermentation etc.
These activities are performed by secretion of enzymes. Hence, this concept is utilized in targeting
various drugs to the colon. The enzymatic reactions carried out by the colonic bacteria are acetylation,
decarboxylation, dehalogenation, dealkylation of O-alkyl groups and N- alkyl groups, desamination,
dehydroxylationesterification, heterocyclic ring fission, hydrolysis, reduction 6,13,17. The activities of
these bacteria is affected by various factors including age, colonic diseases, drugs etc.
7. Strategies for targeting drugs to colon in treatment and prevention of CRC
The systems that are used for CoDDS include pH dependent system, microbial triggered system, pH and
microbial triggered double dependent system and bioadhesive system.
7.1. pH dependent system
This system utilizes the concept of pH in GIT to deliver the drugs in the colon. The drug is either coated
or embedded in the polymer matrix. The polymer used in this system has a pH dependent solubility
whereby it only gets solubilize at the colonic pH and therefore the intact drug molecule can be easily
administered in the colon without its absorption in the upper part of GIT 13. The most commonly used
pH dependent polymers for CoDDS are Eudragit S-100 and Eudragit FS 30D (Evonik) that dissolves at
pH 7 6. This system can be formulated into tablet, capsule, pellets, beads, microparticles, microsphere,
nanoparticles and nanogels 15. The major limitation of this system is lack of specificity and premature
drug release due to drastic variability in the GI pH. One of the studies utilizes this approach to prepare
nanogels. Copolymer of methyl methacrylate and 2 ethyl hexyl acrylate is used as a pH sensitive
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 55
polymer to prepare nanogels of 5 FU using solvent evaporation technique. In vitro release study
confirms the pH sensitive drug release behaviour of this copolymer which shows highest and sustained
release at pH 7.4. Cytotoxicity study was done using HCT-116 cell line whereby it was ascertained that
5 FU loaded nanogels showed higher cytotoxicity as compared to free 5 FU 37.
7.2. Microbial triggered system
This system utilizes the concept of enzymatic degradation by bacteria residing in the colon. The bacteria
present in the colon secrete various enzymes such as, azareducatase, arabinosidase, deaminase,
galactosidase, glucoronidase, nitroreductase, pectinase, urea dehydroxylase, xylosidase etc for the
fermentation of undigested food from the small intestine 15,20. This system uses biodegradable polymers
which protect the drug in the upper part of GIT and gets degraded on reaching the colon resulting in the
drug release. Site specific delivery of drug remains the biggest advantage of this system 6,13,20. Two
approaches can be designed by using this system i. Prodrug approach and ii. Polysaccharide approach.
7.2.1. Prodrug approach
Prodrug is the inactive form of the parent drug molecule which upon enzymatic activation results in the
conversion of active moiety. In this approach the drug is covalently linked with the biodegradable
polymer such that the whole complex is protected from the upper part of the GIT and the drug get
release after reaching the colon by bacterial enzyme. Azo conjugates are the most researched one in this
category 13,15. Prodrug of 5 Fu was synthesized by conjugating 5 FU with a galactose containing
polysaccharide. This prodrug conjugate is intended to release in the colon by colonic enzyme and thus
protecting it from the upper part of GIT where the prodrug conjugate is not able to hydrolyse. When this
prodrug is given to mice, 5 FU is undetectable in the stomach and intestinal tissue but its majority is
detected in distant ileum, cecum, colon and rectum confirming the targeted delivery of 5 FU prodrug to
the colon. In vivo studies of 5-FU prodrug reveal an increase in survival rate as well as decrease in tumor
weight in the treated mice 38.
7.2.2. Polysaccharide approach
Unlike prodrug where the drug is covalently linked to the carrier, this approach uses drug that can be
either coated or embedded in the polysaccharide matrix. An ample of research is going on by using
polysaccharide approach mainly due to its biodegradability and inexpensiveness 15. The combination of
polysaccharide is gaining more importance than using the single one for targeting drugs specifically to
the colon 20. The commonly used polysaccharide includes guar gum, xanthan gum, sodium alginate,
pectin, chitosan. Compression coated tablets were prepared using granulated chitosan as a compression
coat and 5 FU as a model drug, it is checked for targeted delivery to colon. In vitro release studies
revealed that the granulated chitosan protects the formulation from upper part of GIT. Roentgenography
study was done in beagle dogs that confirmed the delivery of drug to the colon with protection in upper
part of the GIT 39.
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 56
7.3. pH and microbial triggered system
This double dependent system utilizes both the approaches whereby the pH sensitive polymer is coated
over a polysaccharide matrix containing the drugs. The role of pH sensitive polymers is to protect the
polysaccharide matrix from the upper part of the GIT where it may get solubilize causing premature
drug release. The main aim of using double dependent systems was to overcome the limitations
associated with both the approaches when used alone. When pH sensitive and polysaccharide approach
is used alone it may cause premature drug release due to high variation in pH of GIT and due to
solubilisation of polymer in the upper part of GIT respectively. These double dependent systems provide
the successful delivery of drug to the colon with least release in the upper part of GIT. Many reports of
CoDDS are available using this approach. One of the studies carried out by Ziyaur Rehman et al, 2006
elaborated on preparation of sodium alginate microsphere of 5 FU using emulsion cross linking method 40. This core microsphere containing drug was coated with Eudragit S-100 which dissolved at pH 7. The
in vitro release studies of both the uncoated and coated microsphere were carried out. The uncoated
microsphere started releasing the drug in the stomach and small intestinal pH but the coated microsphere
restricted the drug release in both the pH thereby releasing the drug in pH 7.4 which mimicked the pH of
the colon. The in vivo pharmacokinetic studies revealed the detection of drug only in the colonic region
which confirmed its targeted delivery to the colon 40, 41. This double dependent approach uses the GI
transit time and the pH of GI tract. In this system the polymer is coated to the time dependent matrix
containing drugs. The polymer coating provides the protection from stomach pH and the time dependent
polymer delay the release until the ileocecal junction 6. A multiunit system consisting of pellets were
prepared and a double coat was applied over it using time dependent coat of Eudragit NE30D and pH
dependent layer of Eudragit FS30D. Avicel PH101 was used as a spheronization aid and HPMC K4M
was used as a binder. The in vitro drug release studies confirmed the release of drug in the colon with
15% w/w of inner and outer coating level 42.
7.4. Bioadhesive system
Bioadhesion is a process in which a dosage form is adhered to the biomembrane allowing longer
residence time thus high local concentration and good absorption. This approach is also used for CoDDS
especially for poorly absorbable drug whereby the dosage form remains intact to the colonic mucosa.
Many bioadhesive polymers have been investigated which include polycarbophils, polyurethanes and
polyethylene oxide, polypropylene oxide copolymers 42. Mucoadhesive microspheres (MAMs) were
prepared by Ahmed MZ et al, 2012 using Assam bora rice starch. Double emulsion solvent evaporation
technique was used to prepare the microsphere. MAMs were checked for its in vitro and in vivo drug
release. The in vitro drug release study assured the insignificant release of drug till 5 h (<8%). The drug
release was 94% till 24 h which confirmed its release in the colon. 5 FU was highly detectable (92%) in
the colon after 8 h and very insignificant amount of 5 FU was detectable in stomach and small intestine.
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 57
Mucoadhesion test was done using goat GI mucous membrane which confirms the highest adhesion of
23 h in the phosphate buffer of pH 7.4 43.
8. CONCLUSION
From a commercial point of view, drug delivery system that is simple and scalable is always preferred.
Designing and manufacturing of complicated system is often costly and not proper. A novel drug
delivery system like CoDDS exhibits improved bioavailability at site and also circumvents side effects.
The technology is robust and dosage form is scalable using standard equipment used in conventional
oral dosage forms. Extensive research has been dedicated to target actives to the colon. Of all the
systems, the pH dependent system and polysaccharide system is considered to be the most feasible and
scalable. Unfortunately, none of the systems described in this review have been developed into a
commercial product to treat CRC.
9. CONTRIBUTORS
Mudassir Ansari and Kavita Singh: All authors equally contributed in this manuscript for the all
tasks.
10. DECLARATION OF INTERESTS
We declare no competing interests.
11. FUNDING: No funding received
12. REFERENCES
1. Patel, M. M. Getting into the Colon: Approaches to Target Colorectal Cancer. Expert Opin. Drug
Deliv. 2014, 11 (9), 1343–1350. https://doi.org/10.1517/17425247.2014.927440.
2. Patel, M. M.; Amin, A. F. Formulation and Development of Release Modulated Colon Targeted
System of Meloxicam for Potential Application in the Prophylaxis of Colorectal Cancer. Drug
Deliv. 2011, 18 (4), 281–293. https://doi.org/10.3109/10717544.2010.538447.
3. Lin, C.; Ng, H.; Pan, W.; Chen, H.; Zhang, G.; Bian, Z.; Lu, A.; Yang, Z. Exploring Different
Strategies for Efficient Delivery of Colorectal Cancer Therapy. Int. J. Mol. Sci. 2015, 16 (11),
26936–26952. https://doi.org/10.3390/ijms161125995.
4. Colorectal Cancer Prevention and Early Detection What Is Colorectal Cancer ?
5. Dna, A. Colorectal Cancer What is cancer ? What is colorectal cancer ?
http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-treating-
radiation-therapy.
6. Krishnaiah, Y. S. R.; Khan, M. a. Strategies of Targeting Oral Drug Delivery Systems to the Colon
and Their Potential Use for the Treatment of Colorectal Cancer. Pharm. Dev. Technol. 2012, 17 (5),
521–540. https://doi.org/10.3109/10837450.2012.696268.
7. Kelloff, G. J.; Schilsky, R. L.; Alberts, D. S.; Day, R. W.; Guyton, K. Z.; Pearce, H. L.; Peck, J. C.;
Phillips, R.; Sigman, C. C. Colorectal Adenomas : A Prototype for the Use of Surrogate End Points
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 58
in the Development of Cancer Prevention Drugs Colorectal Adenomas : A Prototype for the Use of
Surrogate End Points in the Development of Cancer Prevention Drugs. Clin. Cancer Res. 2004, 10
(301), 3908–3918. https://doi.org/10.1158/1078-0432.CCR-03-0789.
8. Stewart, S. L.; Wike, J. M.; Kato, I.; Lewis, D. R.; Michaud, F. A Population-Based Study of
Colorectal Cancer Histology in the United States, 1998-2001. Cancer 2006, 107 (1), 1128–1141.
https://doi.org/10.1002/cncr.22010.
9. Levine, J. S.; Ahnen, D. J. Adenomatous Polyps of the Colon — NEJM. N. Engl. J. Med. 2012, 6
(8), 2551–2557.
10. Bond, J. H. Polyp Guideline: Diagnosis, Treatment, and Surveillance for Patients with Nonfamilial
Colorectal Polyps. The Practice Parameters Committee of the American College of
Gastroenterology. Ann. Intern. Med. 1993, 119 (11), 836–843. https://doi.org/10.1111/j.1572-
0241.2000.03434.x.
11. Jacobson, J. S.; Neugut, A. I. Interpreting Preeursor Studies: What Polyp Trials Tell Us about
Large-Bowel Cancer. J. Natl. Cancer Inst. 1994, 86 (21), 1648.
https://doi.org/10.1093/jnci/86.21.1648.
12. Nasrallah, A.; Saykali, B.; Al Dimassi, S.; Khoury, N.; Hanna, S.; El-Sibai, M. Effect of StarD13 on
Colorectal Cancer Proliferation, Motility and Invasion. Oncol. Rep. 2014, 31 (1), 505–515.
https://doi.org/10.3892/or.2013.2861.
13. Patel, A.; Bhatt, N.; Patel, K. R.; Patel, N. M.; Patel, M. R. Colon Targeted Drug Delivery System :
A Review System. J. Pharm. Sci. Biosci. Res. 2011, 1 (1), 37–49.
14. Challa, T.; Vynala, V.; Allam, K. V. Colon Specific Drug Delivery Systems: A Review on Primary
and Novel Approaches. Int. J. Pharm. Sci. Rev. Res. 2011, 7 (2), 171–181.
15. Rajguru, V. V.; Gaikwad, P. D.; Bankar, V. H.; Pawar, S. P. An Overview on Colonic Drug
Delivery System. Int. J. Pharm. Sci. Rev. Res. 2011, 6 (2), 197–204.
16. Gupta, V. K.; Gnanarajan, G.; Kothiyal, P. THE PHARMA INNOVATION A Review Article on
Colonic Targeted Drug Delivery System INTRODUCTION : Phama Innov. 2012, 1 (7), 14–24.
17. Tiwari, G.; Tiwari, R.; Wal, P.; Wal, A.; Rai, A. K. Primary and Novel Approaches for Colon
Targeted Drug Delivery – A Review. Int. J. Drug Deliv. 2010, 2 (6), 1–11.
https://doi.org/10.5138/ijdd.2010.0975.0215.02006.
18. Kolte, B. P.; Tele, K. V.; Mundhe, V. S.; Lahoti, S. S. Colon Targeted Drug Delivery System – A
Novel Perspective. Asian J. Biomed. Pharm. Sci. 2012, 2 (4), 21–28.
https://doi.org/10.15272/AJBPS.V2I14.131.
19. Philip, A. K.; Philip, B. Colon Targeted Drug Delivery Systems: A Review on Primary and Novel
Approaches. Oman Med J 2010, 25 (2), 79–87. https://doi.org/10.5001/omj.2010.24\nOMJ-D-10-
00028 [pii].
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 59
20. Amidon, S.; Brown, J. E.; Dave, V. S. Colon-Targeted Oral Drug Delivery Systems: Design Trends
and Approaches. AAPS PharmSciTech 2015, 16 (4), 731–741. https://doi.org/10.1208/s12249-015-
0350-9.
21. Markowitz, S. D.; Dawson, D. M.; Willis, J.; Willson, J. K. V. Focus on Colon Cancer. Cancer Cell
2002, 1 (3), 233–236. https://doi.org/10.1016/S1535-6108(02)00053-3.
22. Information, G.; Colon, A. Colon Cancer Treatment ( PDQ ® ) Patient Version Table of Contents.
23. Markowitz, S.; Bertagnolli, M. Molecular Basis of Colorectal Cancer. N. Engl. J. Med. 2009, 361
(25), 2449–2460. https://doi.org/10.1056/NEJMra0804588.Molecular.
24. Bevacizumab, A. Drugs Approved for Colon and Rectal Cancer Drugs Approved for Colon Cancer
Drug Combinations Used in Colon Cancer Drugs Approved for Rectal Cancer Drugs Approved for
Gastroenteropancreatic Neuroendocrine Tumors.
25. Umar, a; Viner, J. L.; Hawk, E. T. The Future of Colon Cancer Prevention. Ann. N. Y. Acad. Sci.
2001, 952 (5), 88–108.
26. Das, D.; Arber, N.; Jankowski, J. A. Chemoprevention of Colorectal Cancer. Digestion 2007, 76 (1),
51–67. https://doi.org/10.1159/000108394.
27. Sporn, M. B. Approaches to Prevention of Epithelial Cancer during the Preneoplastic Period.
Cancer Res. 1976, 36 (7 II), 2699–2702.
28. Shukla, Y.; Pal, S. K. Dietary Cancer Chemoprevention : An Overview. Int. J. Hum. Genet. 2004, 4
(4), 265–276.
29. Kurt Kroenke, Dale Theobald, Jingwei Wu, Julie K. Loza, Janet S. Carpenter, and W. T. The
Association of Depression and Pain with Health-Related Quality of Life, Disability, and Health
Care Use in Cancer Patients. J. Pain Symptom Manage. 2010, 40 (3), 327–341.
https://doi.org/10.1097/MPG.0b013e3181a15ae8.Screening.
30. Harun, Z.; Ghazali, A. R. Potential Chemoprevention Activity of Pterostilbene by Enhancing the
Detoxifying Enzymes in the HT-29 Cell Line. Asian Pacific J. Cancer Prev. 2012, 13 (12), 6403–
6407. https://doi.org/10.7314/APJCP.2012.13.12.6403.
31. Pasi J, A and Robert M, J. Chemoprevention of Colon Cancer. N. Engl. J. Med. 2000, 342 (26),
1960–1968.
32. Karin Gwyn, F. A. S. Chemoprevention of Colorectal Cancer. Am. J. Gastroenterol. 2002, 97 (1),
13–21.
33. Teixeira, M. C.; Braghiroli, M. I.; Sabbaga, J.; Hoff, P. M. Primary Prevention of Colorectal
Cancer: Myth or Reality? World J. Gastroenterol. 2014, 20 (41), 15060–15069.
https://doi.org/10.3748/wjg.v20.i41.15060.
34. Stelmaszuk T, Jałocha L, Wojtuń S, G. J. Chemoprewencja Raka Jelita Grubego [Chemoprevention
of Colorectal Cancer]. Pol Merkur Lek. 2009, 26 (155), 565–568.
The Journal of Pharmaceutical Sciences and Medicinal Research Ansari et al
The J. Pharm. Sci. and Med. Res. (001) (03) (045-060) Page | 60
35. Ali Asgar, L. F.; Chandran, S. Multiparticulate Formulation Approach to Colon Specific Drug
Delivery: Current Perspectives. J. Pharm. Pharm. Sci. 2006, 9 (3), 327–338.
https://doi.org/10.1016/j.jconrel.2008.11.011.
36. Gandhi, B.; Baheti, J. Multiparticulates Drug Delivery Systems : A Review. Int. J. Pharm. Chem.
Sci. 2013, 2 (3), 1620–1626.
37. Ashwanikumar, N.; Kumar, N. A.; Asha Nair, S.; Vinod Kumar, G. S. Methacrylic-Based Nanogels
for the PH-Sensitive Delivery of 5-Fluorouracil in the Colon. Int. J. Nanomedicine 2012, 7 (9),
5769–5779. https://doi.org/10.2147/IJN.S31201.
38. Lengsfeld, C. S.; Shoureshi, R. A. (19) United States (12), 2008.
39. Yassin, A. E. B.; Alsarra, I. a; Alanazi, F. K.; Al-Mohizea, A. M.; Al-Robayan, A. a; Al-Obeed, O.
a. New Targeted-Colon Delivery System: In Vitro and in Vivo Evaluation Using X-Ray Imaging. J.
Drug Target. 2010, 18 (1), 59–66. https://doi.org/10.3109/10611860903165022.
40. Rahman, Z.; Kohli, K.; Khar, R. K.; Ali, M.; Charoo, N. a; Shamsher, A. a a. Characterization of 5-
Fluorouracil Microspheres for Colonic Delivery. AAPS PharmSciTech 2006, 7 (2), E1-9.
https://doi.org/10.1208/pt070247.
41. Rahman, Z.; Kohli, K.; Zhang, S.-Q.; Khar, R. K.; Ali, M.; Charoo, N. a; Tauseef, M.; Shamsher, A.
a a; Mohammed, N. N.; Repka, M. a. In-Vivo Evaluation in Rats of Colon-Specific Microspheres
Containing 5-Fluorouracil. J. Pharm. Pharmacol. 2008, 60 (5), 615–623.
https://doi.org/10.1211/jpp.60.5.0007.
42. Kulthe, S. S.; Bahekar, J. K.; Godhani, C. C.; Choudhari, Y. M.; Inamdar, N. N.; Mourya, V. K.
Modulated Release of 5-Fluorouracil from PH-Sensitive and Colon Targeted Pellets: An Industrially
Feasible Approach. Drug Dev. Ind. Pharm. 2013, 39 (1), 138–145.
https://doi.org/10.3109/03639045.2012.660951.
43. Ahmad, M. Z.; Akhter, S.; Anwar, M.; Ahmad, F. J. Assam Bora Rice Starch Based Biocompatible
Mucoadhesive Microsphere for Targeted Delivery of 5-Fluorouracil in Colorectal Cancer. Mol.
Pharm. 2012, 9 (11), 2986–2994. https://doi.org/10.1021/mp300289y.